ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1725

The SYK Inhibitor Fostamatinib Limits Tissue Damage and Fibrosis in a Bleomycin-Induced Scleroderma MOUSE MODEL

Omer Nuri Pamuk1, Guray Can2, Suleyman Ayvaz3, Turan Karaca4, Gulsum Pamuk5, Selim Demirtas6 and George C. Tsokos7, 1Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, 2Gastroenterology, Trakya University Medical Faculty, Edirne, Turkey, 3Pediatric Surgery, Trakya University Medical Faculty, Edirne, Turkey, 4Histology, Trakya University Medical Faculty, Edirne, Turkey, 5Hematology, Trakya University Medical Faculty, Edirne, Turkey, 6Trakya University Medical Faculty, Edirne, Turkey, 7Rheumatology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Animal models, fibrosis and scleroderma

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Pathogenesis, Animal Models and Genetics

Session Type: Abstract Submissions (ACR)

Background/Purpose The possible antifibrotic effects of various kinase inhibitors has been studied before in SSc. Spleen tyrosine kinase (Syk) is a protein tyrosine kinase which activates intracellular signal transduction pathways and has been claimed to be involved in the pathogenesis of systemic autoimmune diseases. We investigated the ability of a small drug Syk inhibitor, fostamatinib, to protect mice from bleomycin-induced SSc.

Methods Four study groups of Balb/c mice were included in this study: control, bleomycin (administered subcutaneously to BALB/c mice for 21 days), bleomycin and fostamatinib (mice fed with chow containing a Syk inhibitor for 21 days) and fostamatinib alone groups. Skin and lung tissue specimens were obtained and evaluated histologically.

Results Mice treated with bleomycin alone had significantly more skin thickness (416.1±6.1) compared to control (260.1±10.1) and fostamatinib (254.3±7.9) treated mice (p<0.001). Mice subjected to bleomycin and fed with fostamatinib-containing chow generated more (312.3±4.4) dermal thickness than control and fostamatinib-treated mice (p values <0.001) but, significantly less when compared to mice treated with bleomycin alone (p<0.001).Alveolar hemorrhage, edema, damage and leukocyte scores in the lungs of mice treated with bleomycin were significantly higher v compared to control or fostamatinib alone-treated mice (p values <0.001). At the end of the 21-day bleomycin administration, there was apparent prominent fibrosis which was reduced significantly in the group of mice which received in parallel fostamatinib. Following fostamatinib treatment, Syk, phospho-Syk, and TGF-β expression decreased in both skin and lung tissues

Conclusion The Syk inhibitor fostamatinib prevented bleomycin-induced fibrosis and inflammation in the skin and the lung. The anti-fibrotic effect of fostamatinib is linked to reduced Syk phosphorylation and TGF-β expression. The Syk pathway appears as a potential molecular target for therapeutic intervention in SSc.


Disclosure:

O. N. Pamuk,
None;

G. Can,
None;

S. Ayvaz,
None;

T. Karaca,
None;

G. Pamuk,
None;

S. Demirtas,
None;

G. C. Tsokos,
None.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-syk-inhibitor-fostamatinib-limits-tissue-damage-and-fibrosis-in-a-bleomycin-induced-scleroderma-mouse-model/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.